Genetic Technologies (ASX:GTG) Limited offers predictive testing and assessment tools to help physicians proactively manage women’s health. The Company’s lead product,BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.
Our Latest Articles on Genetic Technologies
|Article||02-Oct-2019||GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer|
|Article||14-May-2019||GTG Validates Cancer Tests As it Looks to Global Expansion|
|Article||08-Apr-2019||ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth|
GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer
Oct 2, 2019
Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).